All News

pregnancy,doctor,consult

Worse Birth Outcomes in RA and SLE

d Jack Cush, MD

A population-based retrospective cohort study patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and their infants demonstrated significant adverse pregnancy outcome, particularly the infants of women with SLE.

Read Article
pso.PsA_.NPF_.jpg

Bimekizumab in Active Psoriatic Arthritis - BE COMPLETE study

d Jack Cush, MD

BE COMPLETE is published, showing that bimekizumab (BMK), a selective dual inhibitor of interleukin (IL)-17F and IL-17A, results in superior improvement in both skin and joint outcomes in psoriatic arthritis (PsA) patients who have previously failed treatment with a tumour necrosis factor-α (TNFα) inhibitor.

Read Article
T%20cell.jpg

Holes in TH17 cells release IL-1α on NLRP3 activation

d EurekAlert!

Certain T cells can secrete cytokines that are normally part of the innate immune system, as researchers from the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI) and an international research team discovered.

Read Article
PMR spotlight

JAK Inhibitor Promising for Polymyalgia Rheumatica

d MedPage Today

Tofacitinib (Xeljanz) appeared highly effective against polymyalgia rheumatica (PMR) in a small single-arm trial, researchers said, suggesting another potential alternative to long-term corticosteroids.

Read Article
Hosp study of 2809 admissions, found 1+adverse events (AE) in 24%. Among 978 AE, 23% (222) were preventable; 32% (316) serious. Preventable AE occurred in 1/15 admissions (serious 1/100). Drug AE were most common (39%) https://t.co/gqty53ccyH https://t.co/GxDBoEhxeM

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitor Promising for Polymyalgia Rheumatica Tofacitinib appeared highly effective against PMR in a small single-arm trial, researchers said, suggesting another potential alternative to long-term corticosteroids. https://t.co/XNhICcDU7t https://t.co/WWHNRP3aeP

Links:

Dr. John Cush RheumNow ( View Tweet)
"It takes alot of courage to reach out and say 'I need some help on this one'" (Carla Harris) Put on your big-boy pants, woman-up and ask for advice, not from anyone - go to the right person/people - you know who they are! https://t.co/GUs1nCvXeU
Dr. John Cush RheumNow ( View Tweet)
Holes in TH17 cells release IL-1α on NLRP3 activation Certain T cells can secrete cytokines that are normally part of the innate immune system, as researchers from the Leibniz-HKI and an international research team discovered. https://t.co/lLHD66D3RP https://t.co/cym7SGD2WX

Links:

Dr. John Cush RheumNow ( View Tweet)
Free great handout on DRESS - Drug Reaction With Eosinophilia and Systemic Symptoms. May affect adults or children; usually 2 to 8 weeks after beginning a medication. ~1 in 1000 taking specific drugs get DRESS. Allopurinol is a common cause https://t.co/X8lHtGVunC https://t.co/OjCzUXWJcz

Links:

Dr. John Cush RheumNow ( View Tweet)
anti-mitochondrial antibodies (AMA) in were assayed in 404 #RA patients & found to positive in 14-26%. Importantly AMA Abs were associated with erosive disease (p<0.05) and interstitial lung disease (p<0.01), independent of CCP or RF https://t.co/ZcrOYr0cWX https://t.co/KvZ3N5IiCB

Links:

Dr. John Cush RheumNow ( View Tweet)
10 best US jobs in2023, half are medical 1 Software developer 2 Nurse practioner 3 Medical/health serv manager 4 Physician asst 5 Information security analyst 6 Physical therapist 7 Financial manager 8 IT Manager 9 Web developer 10 Dentist https://t.co/nL5yuorzTH https://t.co/4mYspRCZX0

Links:

Dr. John Cush RheumNow ( View Tweet)
Cannabis Use for Pain is Common In states with legalized medical cannabis use, 3 in 10 persons are using cannabis to manage their pain. https://t.co/XUt1E7GcQN https://t.co/4l6vYKUOQs

Links:

Dr. John Cush RheumNow ( View Tweet)
Treatment Considerations in Axial Spondyloarthritis https://t.co/GRQfk4B4QN https://t.co/xX5AYAD90c

Links:

Dr. John Cush RheumNow ( View Tweet)
2022 Memorium Sadly, too many of our rheumatology colleagues passed on in 2022. Here is an (incomplete) list of notable brethren, mentors, do-gooders and great rheumatologists. https://t.co/wtr4ablgUm https://t.co/xPpgnrEQWz

Links:

Dr. John Cush RheumNow ( View Tweet)
2022 Rheumatology Year in Review Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown. https://t.co/6r6W95moyr https://t.co/PNlMDId7qX

Links:

Dr. John Cush RheumNow ( View Tweet)
AutoAb analysis of 140 systemic sclerosis shows low sensitivity (<33%), high specificity (>88%). Scl-70+ signif assoc w sine scleroderma, digital ulcers, Raynauds as 1st onset sign. SSc-ILD more common Scl-70 and PAH with CENP A/B Abs https://t.co/1zvkte4drJ https://t.co/FaSmshUvhY

Links:

Dr. John Cush RheumNow ( View Tweet)
PsABiostudy followed PsA pts starting TNFi vs ustekinumab x12 mos showing equivalent durability at 1 yr (72% vs 71%). cDAPSA LDA was seen in 56% UST vs 67% TNFi (similar for MDA (34% vs 43%) https://t.co/briK7itZtL https://t.co/Rq1SXA7s1s

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Database 1,955 breakthrough COVID-19 infxs in 54,576 #gout pts compared to 52,468 w/o gout saw more in gout (adj HR 1.24), also w/ more #COVID hospitalizations (adj HR 1.30) & death (1.36), more so in women. Same for unvaccinated https://t.co/596KvupZxi https://t.co/BJJguQBdin

Links:

Dr. John Cush RheumNow ( View Tweet)
Autoimmune Dz may be assoc w/ new-onset Atrial Fibrillation, esp in women. Population-based UK Biobank found significant increases for AFib in Rheumatic fever w/o CVD (HR 1.47), Crohn’ (1.23), UC(1.17), RA (1.39), PAN (1.82), SLE (1.82), PSS (2.32) https://t.co/rpIiztUfg9 https://t.co/FWmLiZ6x1S

Links:

Dr. John Cush RheumNow ( View Tweet)
Abbvie has forcasted sales sales revenues in 2025 for Skyrizi and Rinvoq to be more than $17.5 billion. This year Humira goes off patent. https://t.co/YrIdkEhL7M https://t.co/MuuVYkyXRv

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×